According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
BLRX has been the topic of a number of other reports. HC Wainwright reaffirmed a “neutral” rating on shares of BIOLINERX LTD/S in a research note on Wednesday, August 7th. Maxim Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of BIOLINERX LTD/S in a research note on Monday, July 22nd. Finally, ValuEngine cut BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $4.75.
BIOLINERX LTD/S (NASDAQ:BLRX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.61. As a group, sell-side analysts forecast that BIOLINERX LTD/S will post -2.66 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc increased its stake in BIOLINERX LTD/S by 82.5% in the 2nd quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 33,000 shares during the period. Delek Group Ltd. increased its stake in BIOLINERX LTD/S by 74.0% in the 2nd quarter. Delek Group Ltd. now owns 375,047 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 159,469 shares during the period. Finally, Morgan Stanley increased its stake in BIOLINERX LTD/S by 50.6% in the 2nd quarter. Morgan Stanley now owns 1,421,862 shares of the biotechnology company’s stock worth $519,000 after purchasing an additional 477,798 shares during the period.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
See Also: What is a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.